Sequenta

Sequenta

Sequenta

is dedicated to improving patient care in diseases mediated by immune cells. Our ClonoSIGHT™ test for MRD in lymphoid cancers launched in 2013.
Founded
2008
Raised
$41.5M
Follow us
Alexa global traffic share
Twitter followers
Acquired by
Adaptive Biotech
07 Jan 2015
Latest funding Show all
Undisclosed amount
Venture capital - 2014
Celgene
$20,000,000
Venture capital (Series C) - 2013
Foresite Capital
Venture capital
businesswire

Celgene Participates in New Round of Investment for Sequenta